#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Influenza A virus ( IAV ) , a member of the Orthomyxoviridae family , is a negative-sense , single-stranded , enveloped , segmented RNA virus .
3-1	17-26	Influenza	abstract	new	appos	3-2[4_0]
3-2	27-28	A	abstract[4]	giv[4]	appos	3-5[0_4]
3-3	29-34	virus	abstract[4]	giv[4]	_	_
3-4	35-36	(	_	_	_	_
3-5	37-40	IAV	abstract	giv	coref	3-16[8_0]
3-6	41-42	)	_	_	_	_
3-7	43-44	,	_	_	_	_
3-8	45-46	a	person[6]	new[6]	_	_
3-9	47-53	member	person[6]	new[6]	_	_
3-10	54-56	of	person[6]	new[6]	_	_
3-11	57-60	the	person[6]|abstract[7]	new[6]|new[7]	_	_
3-12	61-77	Orthomyxoviridae	person[6]|abstract[7]	new[6]|new[7]	_	_
3-13	78-84	family	person[6]|abstract[7]	new[6]|new[7]	_	_
3-14	85-86	,	_	_	_	_
3-15	87-89	is	_	_	_	_
3-16	90-91	a	abstract[8]	giv[8]	coref	4-1[0_8]
3-17	92-106	negative-sense	abstract[8]	giv[8]	_	_
3-18	107-108	,	abstract[8]	giv[8]	_	_
3-19	109-124	single-stranded	abstract[8]	giv[8]	_	_
3-20	125-126	,	abstract[8]	giv[8]	_	_
3-21	127-136	enveloped	abstract[8]	giv[8]	_	_
3-22	137-138	,	abstract[8]	giv[8]	_	_
3-23	139-148	segmented	abstract[8]	giv[8]	_	_
3-24	149-152	RNA	abstract[8]	giv[8]	_	_
3-25	153-158	virus	abstract[8]	giv[8]	_	_
3-26	159-160	.	_	_	_	_

#Text=IAV usually infects epithelial cells of the upper and lower respiratory tracts , including the nasal mucosa , trachea , and lungs , with no evident symptoms during the early phase of infection .
4-1	161-164	IAV	abstract	giv	coref	5-3
4-2	165-172	usually	_	_	_	_
4-3	173-180	infects	_	_	_	_
4-4	181-191	epithelial	object[10]	new[10]	coref	5-18[23_10]
4-5	192-197	cells	object[10]	new[10]	_	_
4-6	198-200	of	object[10]	new[10]	_	_
4-7	201-204	the	object[10]|object[11]	new[10]|new[11]	_	_
4-8	205-210	upper	object[10]|object[11]	new[10]|new[11]	_	_
4-9	211-214	and	object[10]|object[11]	new[10]|new[11]	_	_
4-10	215-220	lower	object[10]|object[11]	new[10]|new[11]	_	_
4-11	221-232	respiratory	object[10]|object[11]	new[10]|new[11]	_	_
4-12	233-239	tracts	object[10]|object[11]	new[10]|new[11]	_	_
4-13	240-241	,	object[10]|object[11]	new[10]|new[11]	_	_
4-14	242-251	including	object[10]|object[11]	new[10]|new[11]	_	_
4-15	252-255	the	object[10]|object[11]|object[12]	new[10]|new[11]|new[12]	_	_
4-16	256-261	nasal	object[10]|object[11]|object[12]	new[10]|new[11]|new[12]	_	_
4-17	262-268	mucosa	object[10]|object[11]|object[12]	new[10]|new[11]|new[12]	_	_
4-18	269-270	,	object[10]|object[11]	new[10]|new[11]	_	_
4-19	271-278	trachea	object[10]|object[11]|object	new[10]|new[11]|new	_	_
4-20	279-280	,	object[10]|object[11]	new[10]|new[11]	_	_
4-21	281-284	and	object[10]|object[11]	new[10]|new[11]	_	_
4-22	285-290	lungs	object[10]|object[11]|object[14]	new[10]|new[11]|new[14]	_	_
4-23	291-292	,	object[10]|object[11]|object[14]	new[10]|new[11]|new[14]	_	_
4-24	293-297	with	object[10]|object[11]|object[14]	new[10]|new[11]|new[14]	_	_
4-25	298-300	no	object[10]|object[11]|object[14]|abstract[15]	new[10]|new[11]|new[14]|new[15]	_	_
4-26	301-308	evident	object[10]|object[11]|object[14]|abstract[15]	new[10]|new[11]|new[14]|new[15]	_	_
4-27	309-317	symptoms	object[10]|object[11]|object[14]|abstract[15]	new[10]|new[11]|new[14]|new[15]	_	_
4-28	318-324	during	object[10]|object[11]|object[14]|abstract[15]	new[10]|new[11]|new[14]|new[15]	_	_
4-29	325-328	the	object[10]|object[11]|object[14]|abstract[15]|abstract[16]	new[10]|new[11]|new[14]|new[15]|new[16]	_	_
4-30	329-334	early	object[10]|object[11]|object[14]|abstract[15]|abstract[16]	new[10]|new[11]|new[14]|new[15]|new[16]	_	_
4-31	335-340	phase	object[10]|object[11]|object[14]|abstract[15]|abstract[16]	new[10]|new[11]|new[14]|new[15]|new[16]	_	_
4-32	341-343	of	object[10]|object[11]|object[14]|abstract[15]|abstract[16]	new[10]|new[11]|new[14]|new[15]|new[16]	_	_
4-33	344-353	infection	object[10]|object[11]|object[14]|abstract[15]|abstract[16]|abstract	new[10]|new[11]|new[14]|new[15]|new[16]|new	coref	6-12[29_0]
4-34	354-355	.	_	_	_	_

#Text=Once an influenza virus invasion occurs , innate immunity is activated , and interferons are secreted by host cells to limit the early viral proliferation .
5-1	356-360	Once	_	_	_	_
5-2	361-363	an	event[20]	new[20]	_	_
5-3	364-373	influenza	abstract|event[20]	giv|new[20]	coref	5-4
5-4	374-379	virus	abstract|event[20]	giv|new[20]	coref	7-9
5-5	380-388	invasion	event[20]	new[20]	_	_
5-6	389-395	occurs	_	_	_	_
5-7	396-397	,	_	_	_	_
5-8	398-404	innate	abstract[21]	new[21]	coref	6-3[26_21]
5-9	405-413	immunity	abstract[21]	new[21]	_	_
5-10	414-416	is	_	_	_	_
5-11	417-426	activated	_	_	_	_
5-12	427-428	,	_	_	_	_
5-13	429-432	and	_	_	_	_
5-14	433-444	interferons	substance	new	_	_
5-15	445-448	are	_	_	_	_
5-16	449-457	secreted	_	_	_	_
5-17	458-460	by	_	_	_	_
5-18	461-465	host	object[23]	giv[23]	coref	8-6[43_23]
5-19	466-471	cells	object[23]	giv[23]	_	_
5-20	472-474	to	_	_	_	_
5-21	475-480	limit	_	_	_	_
5-22	481-484	the	abstract[25]	new[25]	coref	11-12[79_25]
5-23	485-490	early	abstract[25]	new[25]	_	_
5-24	491-496	viral	organization|abstract[25]	new|new[25]	coref	6-12
5-25	497-510	proliferation	abstract[25]	new[25]	_	_
5-26	511-512	.	_	_	_	_

#Text=Then , adaptive immunity is activated by other cytokines produced during viral infection .
6-1	513-517	Then	_	_	_	_
6-2	518-519	,	_	_	_	_
6-3	520-528	adaptive	abstract[26]	giv[26]	coref	18-14[145_26]
6-4	529-537	immunity	abstract[26]	giv[26]	_	_
6-5	538-540	is	_	_	_	_
6-6	541-550	activated	_	_	_	_
6-7	551-553	by	_	_	_	_
6-8	554-559	other	abstract[27]	new[27]	coref	7-21[37_27]
6-9	560-569	cytokines	abstract[27]	new[27]	_	_
6-10	570-578	produced	_	_	_	_
6-11	579-585	during	_	_	_	_
6-12	586-591	viral	object|abstract[29]	giv|giv[29]	coref|coref|coref|coref	8-41|11-3[77_29]|8-41|11-3[77_29]
6-13	592-601	infection	abstract[29]	giv[29]	_	_
6-14	602-603	.	_	_	_	_

#Text=However , in some cases , highly pathogenic influenza viruses induce cytokine storms , a consequence of excessive production of cytokines and interferon , resulting in infections and even death .
7-1	604-611	However	_	_	_	_
7-2	612-613	,	_	_	_	_
7-3	614-616	in	_	_	_	_
7-4	617-621	some	abstract[30]	new[30]	_	_
7-5	622-627	cases	abstract[30]	new[30]	_	_
7-6	628-629	,	_	_	_	_
7-7	630-636	highly	object[32]	new[32]	coref	9-7[59_32]
7-8	637-647	pathogenic	object[32]	new[32]	_	_
7-9	648-657	influenza	abstract|object[32]	giv|new[32]	coref	8-3
7-10	658-665	viruses	object[32]	new[32]	_	_
7-11	666-672	induce	_	_	_	_
7-12	673-681	cytokine	substance|abstract[34]	new|new[34]	appos|appos	7-15[35_34]|7-15[35_34]
7-13	682-688	storms	abstract[34]	new[34]	_	_
7-14	689-690	,	_	_	_	_
7-15	691-692	a	abstract[35]	giv[35]	_	_
7-16	693-704	consequence	abstract[35]	giv[35]	_	_
7-17	705-707	of	abstract[35]	giv[35]	_	_
7-18	708-717	excessive	abstract[35]|abstract[36]	giv[35]|new[36]	_	_
7-19	718-728	production	abstract[35]|abstract[36]	giv[35]|new[36]	_	_
7-20	729-731	of	abstract[35]|abstract[36]	giv[35]|new[36]	_	_
7-21	732-741	cytokines	abstract[35]|abstract[36]|abstract[37]	giv[35]|new[36]|giv[37]	_	_
7-22	742-745	and	abstract[35]|abstract[36]|abstract[37]	giv[35]|new[36]|giv[37]	_	_
7-23	746-756	interferon	abstract[35]|abstract[36]|abstract[37]|organization	giv[35]|new[36]|giv[37]|new	_	_
7-24	757-758	,	_	_	_	_
7-25	759-768	resulting	_	_	_	_
7-26	769-771	in	_	_	_	_
7-27	772-782	infections	abstract	new	_	_
7-28	783-786	and	_	_	_	_
7-29	787-791	even	event[40]	new[40]	_	_
7-30	792-797	death	event[40]	new[40]	_	_
7-31	798-799	.	_	_	_	_

#Text=To facilitate virus replication in the host cells , IAV has evolved strategies to block the innate and adaptive immune responses of the host cells and seize organelles from host cells to synthesize a large number of metabolites required for viral reproduction , as well as energy for the packaging of the virus .
8-1	800-802	To	_	_	_	_
8-2	803-813	facilitate	_	_	_	_
8-3	814-819	virus	abstract|abstract[42]	giv|new[42]	coref|coref|coref|coref	8-10|9-29[67_42]|8-10|9-29[67_42]
8-4	820-831	replication	abstract[42]	new[42]	_	_
8-5	832-834	in	_	_	_	_
8-6	835-838	the	object[43]	giv[43]	coref	8-23[48_43]
8-7	839-843	host	object[43]	giv[43]	_	_
8-8	844-849	cells	object[43]	giv[43]	_	_
8-9	850-851	,	_	_	_	_
8-10	852-855	IAV	organization	giv	coref	8-52[57_0]
8-11	856-859	has	_	_	_	_
8-12	860-867	evolved	_	_	_	_
8-13	868-878	strategies	abstract	new	coref	18-27[150_0]
8-14	879-881	to	_	_	_	_
8-15	882-887	block	_	_	_	_
8-16	888-891	the	abstract[47]	new[47]	_	_
8-17	892-898	innate	abstract[47]	new[47]	_	_
8-18	899-902	and	abstract[47]	new[47]	_	_
8-19	903-911	adaptive	abstract[47]	new[47]	_	_
8-20	912-918	immune	abstract|abstract[47]	new|new[47]	coref	17-14
8-21	919-928	responses	abstract[47]	new[47]	_	_
8-22	929-931	of	abstract[47]	new[47]	_	_
8-23	932-935	the	abstract[47]|object[48]	new[47]|giv[48]	coref	8-30[50_48]
8-24	936-940	host	abstract[47]|object[48]	new[47]|giv[48]	_	_
8-25	941-946	cells	abstract[47]|object[48]	new[47]|giv[48]	_	_
8-26	947-950	and	_	_	_	_
8-27	951-956	seize	_	_	_	_
8-28	957-967	organelles	object	new	_	_
8-29	968-972	from	_	_	_	_
8-30	973-977	host	object[50]	giv[50]	coref	10-11[73_50]
8-31	978-983	cells	object[50]	giv[50]	_	_
8-32	984-986	to	_	_	_	_
8-33	987-997	synthesize	_	_	_	_
8-34	998-999	a	abstract[51]	new[51]	_	_
8-35	1000-1005	large	abstract[51]	new[51]	_	_
8-36	1006-1012	number	abstract[51]	new[51]	_	_
8-37	1013-1015	of	abstract[51]	new[51]	_	_
8-38	1016-1027	metabolites	abstract[51]|substance	new[51]|new	coref	9-10[61_0]
8-39	1028-1036	required	abstract[51]	new[51]	_	_
8-40	1037-1040	for	abstract[51]	new[51]	_	_
8-41	1041-1046	viral	abstract[51]|organization|abstract[54]	new[51]|giv|new[54]	_	_
8-42	1047-1059	reproduction	abstract[51]|abstract[54]	new[51]|new[54]	_	_
8-43	1060-1061	,	abstract[51]	new[51]	_	_
8-44	1062-1064	as	abstract[51]	new[51]	_	_
8-45	1065-1069	well	abstract[51]	new[51]	_	_
8-46	1070-1072	as	abstract[51]	new[51]	_	_
8-47	1073-1079	energy	abstract[51]|abstract[55]	new[51]|new[55]	_	_
8-48	1080-1083	for	abstract[51]|abstract[55]	new[51]|new[55]	_	_
8-49	1084-1087	the	abstract[51]|abstract[55]|abstract[56]	new[51]|new[55]|new[56]	_	_
8-50	1088-1097	packaging	abstract[51]|abstract[55]|abstract[56]	new[51]|new[55]|new[56]	_	_
8-51	1098-1100	of	abstract[51]|abstract[55]|abstract[56]	new[51]|new[55]|new[56]	_	_
8-52	1101-1104	the	abstract[51]|abstract[55]|abstract[56]|abstract[57]	new[51]|new[55]|new[56]|giv[57]	coref	10-19[75_57]
8-53	1105-1110	virus	abstract[51]|abstract[55]|abstract[56]|abstract[57]	new[51]|new[55]|new[56]|giv[57]	_	_
8-54	1111-1112	.	_	_	_	_

#Text=Enveloped , non-enveloped , DNA and RNA viruses share lipid metabolites in their replication cycles to induce the formation of new cytoplasmic membrane structures , which contribute to the replication and packaging of the viral genome .
9-1	1113-1122	Enveloped	_	_	_	_
9-2	1123-1124	,	_	_	_	_
9-3	1125-1138	non-enveloped	_	_	_	_
9-4	1139-1140	,	_	_	_	_
9-5	1141-1144	DNA	substance	new	_	_
9-6	1145-1148	and	_	_	_	_
9-7	1149-1152	RNA	object[59]	giv[59]	coref	13-33[104_59]
9-8	1153-1160	viruses	object[59]	giv[59]	_	_
9-9	1161-1166	share	_	_	_	_
9-10	1167-1172	lipid	person|substance[61]	new|giv[61]	ana|coref|ana|coref	9-13[0_61]|10-1|9-13[0_61]|10-1
9-11	1173-1184	metabolites	substance[61]	giv[61]	_	_
9-12	1185-1187	in	_	_	_	_
9-13	1188-1193	their	substance|abstract[63]	giv|new[63]	coref|coref	12-5[85_0]|12-5[85_0]
9-14	1194-1205	replication	abstract[63]	new[63]	_	_
9-15	1206-1212	cycles	abstract[63]	new[63]	_	_
9-16	1213-1215	to	_	_	_	_
9-17	1216-1222	induce	_	_	_	_
9-18	1223-1226	the	abstract[64]	new[64]	_	_
9-19	1227-1236	formation	abstract[64]	new[64]	_	_
9-20	1237-1239	of	abstract[64]	new[64]	_	_
9-21	1240-1243	new	abstract[64]|abstract[66]	new[64]|new[66]	_	_
9-22	1244-1255	cytoplasmic	abstract[64]|abstract[66]	new[64]|new[66]	_	_
9-23	1256-1264	membrane	abstract[64]|object|abstract[66]	new[64]|new|new[66]	_	_
9-24	1265-1275	structures	abstract[64]|abstract[66]	new[64]|new[66]	_	_
9-25	1276-1277	,	_	_	_	_
9-26	1278-1283	which	_	_	_	_
9-27	1284-1294	contribute	_	_	_	_
9-28	1295-1297	to	_	_	_	_
9-29	1298-1301	the	abstract[67]	giv[67]	coref	10-15[74_67]
9-30	1302-1313	replication	abstract[67]	giv[67]	_	_
9-31	1314-1317	and	_	_	_	_
9-32	1318-1327	packaging	abstract[68]	new[68]	_	_
9-33	1328-1330	of	abstract[68]	new[68]	_	_
9-34	1331-1334	the	abstract[68]|object[69]	new[68]|new[69]	_	_
9-35	1335-1340	viral	abstract[68]|object[69]	new[68]|new[69]	_	_
9-36	1341-1347	genome	abstract[68]|object[69]	new[68]|new[69]	_	_
9-37	1348-1349	.	_	_	_	_

#Text=Lipid metabolism also can block the innate immune response of host cells to ensure the large-scale replication of the virus .
10-1	1350-1355	Lipid	object|abstract[71]	giv|new[71]	coref|coref	11-9[0_71]|11-9[0_71]
10-2	1356-1366	metabolism	abstract[71]	new[71]	_	_
10-3	1367-1371	also	_	_	_	_
10-4	1372-1375	can	_	_	_	_
10-5	1376-1381	block	_	_	_	_
10-6	1382-1385	the	abstract[72]	new[72]	_	_
10-7	1386-1392	innate	abstract[72]	new[72]	_	_
10-8	1393-1399	immune	abstract[72]	new[72]	_	_
10-9	1400-1408	response	abstract[72]	new[72]	_	_
10-10	1409-1411	of	abstract[72]	new[72]	_	_
10-11	1412-1416	host	abstract[72]|object[73]	new[72]|giv[73]	coref	14-20[0_73]
10-12	1417-1422	cells	abstract[72]|object[73]	new[72]|giv[73]	_	_
10-13	1423-1425	to	_	_	_	_
10-14	1426-1432	ensure	_	_	_	_
10-15	1433-1436	the	abstract[74]	giv[74]	_	_
10-16	1437-1448	large-scale	abstract[74]	giv[74]	_	_
10-17	1449-1460	replication	abstract[74]	giv[74]	_	_
10-18	1461-1463	of	abstract[74]	giv[74]	_	_
10-19	1464-1467	the	abstract[74]|abstract[75]	giv[74]|giv[75]	coref	11-3[0_75]
10-20	1468-1473	virus	abstract[74]|abstract[75]	giv[74]|giv[75]	_	_
10-21	1474-1475	.	_	_	_	_

#Text=Therefore , IAV infection is linked closely to metabolism , and the proliferation of the virus also is inseparable from the host metabolism .
11-1	1476-1485	Therefore	_	_	_	_
11-2	1486-1487	,	_	_	_	_
11-3	1488-1491	IAV	object|abstract[77]	giv|giv[77]	coref|coref|coref|coref	11-15[80_0]|14-8[112_77]|11-15[80_0]|14-8[112_77]
11-4	1492-1501	infection	abstract[77]	giv[77]	_	_
11-5	1502-1504	is	_	_	_	_
11-6	1505-1511	linked	_	_	_	_
11-7	1512-1519	closely	_	_	_	_
11-8	1520-1522	to	_	_	_	_
11-9	1523-1533	metabolism	abstract	giv	coref	11-21[82_0]
11-10	1534-1535	,	_	_	_	_
11-11	1536-1539	and	_	_	_	_
11-12	1540-1543	the	abstract[79]	giv[79]	_	_
11-13	1544-1557	proliferation	abstract[79]	giv[79]	_	_
11-14	1558-1560	of	abstract[79]	giv[79]	_	_
11-15	1561-1564	the	abstract[79]|abstract[80]	giv[79]|giv[80]	coref	13-10[0_80]
11-16	1565-1570	virus	abstract[79]|abstract[80]	giv[79]|giv[80]	_	_
11-17	1571-1575	also	_	_	_	_
11-18	1576-1578	is	_	_	_	_
11-19	1579-1590	inseparable	_	_	_	_
11-20	1591-1595	from	_	_	_	_
11-21	1596-1599	the	abstract[82]	giv[82]	coref	16-9[128_82]
11-22	1600-1604	host	person|abstract[82]	new|giv[82]	coref	12-14
11-23	1605-1615	metabolism	abstract[82]	giv[82]	_	_
11-24	1616-1617	.	_	_	_	_

#Text=This changing trend in small molecule metabolites may serve as a characterization of host – pathogen interactions to monitor immune status .
12-1	1618-1622	This	abstract[83]	new[83]	_	_
12-2	1623-1631	changing	abstract[83]	new[83]	_	_
12-3	1632-1637	trend	abstract[83]	new[83]	_	_
12-4	1638-1640	in	abstract[83]	new[83]	_	_
12-5	1641-1646	small	abstract[83]|substance[85]	new[83]|giv[85]	_	_
12-6	1647-1655	molecule	abstract[83]|abstract|substance[85]	new[83]|new|giv[85]	_	_
12-7	1656-1667	metabolites	abstract[83]|substance[85]	new[83]|giv[85]	_	_
12-8	1668-1671	may	_	_	_	_
12-9	1672-1677	serve	_	_	_	_
12-10	1678-1680	as	_	_	_	_
12-11	1681-1682	a	_	_	_	_
12-12	1683-1699	characterization	_	_	_	_
12-13	1700-1702	of	_	_	_	_
12-14	1703-1707	host	person	giv	coref	18-23[148_0]
12-15	1708-1709	–	_	_	_	_
12-16	1710-1718	pathogen	abstract|abstract[88]	new|new[88]	_	_
12-17	1719-1731	interactions	abstract[88]	new[88]	_	_
12-18	1732-1734	to	_	_	_	_
12-19	1735-1742	monitor	_	_	_	_
12-20	1743-1749	immune	abstract[89]	new[89]	_	_
12-21	1750-1756	status	abstract[89]	new[89]	_	_
12-22	1757-1758	.	_	_	_	_

#Text=Although significant progress has been made toward an anti-influenza virus drug discovery , including M2 ion channel blockers , neuraminidase inhibitors , and polymerase inhibitors , challenges posed by drug toxicity and viruses with genetic resistance remain a serious problem .
13-1	1759-1767	Although	_	_	_	_
13-2	1768-1779	significant	abstract[90]	new[90]	_	_
13-3	1780-1788	progress	abstract[90]	new[90]	_	_
13-4	1789-1792	has	_	_	_	_
13-5	1793-1797	been	_	_	_	_
13-6	1798-1802	made	_	_	_	_
13-7	1803-1809	toward	_	_	_	_
13-8	1810-1812	an	abstract[93]	new[93]	_	_
13-9	1813-1827	anti-influenza	abstract[93]	new[93]	_	_
13-10	1828-1833	virus	abstract|abstract[93]	giv|new[93]	coref	14-8
13-11	1834-1838	drug	substance|abstract[93]	new|new[93]	coref	13-30
13-12	1839-1848	discovery	abstract[93]	new[93]	_	_
13-13	1849-1850	,	abstract[93]	new[93]	_	_
13-14	1851-1860	including	abstract[93]	new[93]	_	_
13-15	1861-1863	M2	abstract[93]|abstract|abstract[96]	new[93]|new|new[96]	_	_
13-16	1864-1867	ion	abstract[93]|abstract[96]	new[93]|new[96]	_	_
13-17	1868-1875	channel	abstract[93]|place|abstract[96]	new[93]|new|new[96]	_	_
13-18	1876-1884	blockers	abstract[93]|abstract[96]	new[93]|new[96]	_	_
13-19	1885-1886	,	abstract[93]	new[93]	_	_
13-20	1887-1900	neuraminidase	abstract[93]|abstract|object[98]	new[93]|new|new[98]	_	_
13-21	1901-1911	inhibitors	abstract[93]|object[98]	new[93]|new[98]	_	_
13-22	1912-1913	,	abstract[93]	new[93]	_	_
13-23	1914-1917	and	abstract[93]	new[93]	_	_
13-24	1918-1928	polymerase	abstract[93]|object|object[100]	new[93]|new|new[100]	_	_
13-25	1929-1939	inhibitors	abstract[93]|object[100]	new[93]|new[100]	_	_
13-26	1940-1941	,	_	_	_	_
13-27	1942-1952	challenges	abstract	new	_	_
13-28	1953-1958	posed	_	_	_	_
13-29	1959-1961	by	_	_	_	_
13-30	1962-1966	drug	substance|abstract[103]	giv|new[103]	_	_
13-31	1967-1975	toxicity	abstract[103]	new[103]	_	_
13-32	1976-1979	and	_	_	_	_
13-33	1980-1987	viruses	object[104]	giv[104]	_	_
13-34	1988-1992	with	object[104]	giv[104]	_	_
13-35	1993-2000	genetic	object[104]|abstract[105]	giv[104]|new[105]	_	_
13-36	2001-2011	resistance	object[104]|abstract[105]	giv[104]|new[105]	_	_
13-37	2012-2018	remain	_	_	_	_
13-38	2019-2020	a	abstract[106]	new[106]	_	_
13-39	2021-2028	serious	abstract[106]	new[106]	_	_
13-40	2029-2036	problem	abstract[106]	new[106]	_	_
13-41	2037-2038	.	_	_	_	_

#Text=Previous research demonstrated the metabolic effects of influenza virus infection in Madin – Darby canine kidney ( MDCK ) cells , displaying the intra- and extra-cellular metabolite profiling upon IAV infection .
14-1	2039-2047	Previous	abstract[107]	new[107]	_	_
14-2	2048-2056	research	abstract[107]	new[107]	_	_
14-3	2057-2069	demonstrated	_	_	_	_
14-4	2070-2073	the	abstract[109]	new[109]	_	_
14-5	2074-2083	metabolic	abstract|abstract[109]	new|new[109]	coref	15-10
14-6	2084-2091	effects	abstract[109]	new[109]	_	_
14-7	2092-2094	of	abstract[109]	new[109]	_	_
14-8	2095-2104	influenza	abstract[109]|abstract|abstract[112]	new[109]|giv|giv[112]	coref|coref|coref|coref	14-9|14-30[118_112]|14-9|14-30[118_112]
14-9	2105-2110	virus	abstract[109]|abstract|abstract[112]	new[109]|giv|giv[112]	coref	14-30
14-10	2111-2120	infection	abstract[109]|abstract[112]	new[109]|giv[112]	_	_
14-11	2121-2123	in	abstract[109]|abstract[112]	new[109]|giv[112]	_	_
14-12	2124-2129	Madin	abstract[109]|abstract[112]|person	new[109]|giv[112]|new	_	_
14-13	2130-2131	–	abstract[109]|abstract[112]	new[109]|giv[112]	_	_
14-14	2132-2137	Darby	abstract[109]|abstract[112]	new[109]|giv[112]	_	_
14-15	2138-2144	canine	abstract[109]|abstract[112]	new[109]|giv[112]	_	_
14-16	2145-2151	kidney	abstract[109]|abstract[112]	new[109]|giv[112]	_	_
14-17	2152-2153	(	abstract[109]|abstract[112]	new[109]|giv[112]	_	_
14-18	2154-2158	MDCK	abstract[109]|abstract[112]|object	new[109]|giv[112]|new	_	_
14-19	2159-2160	)	abstract[109]|abstract[112]	new[109]|giv[112]	_	_
14-20	2161-2166	cells	abstract[109]|abstract[112]|object	new[109]|giv[112]|giv	coref	16-15[132_0]
14-21	2167-2168	,	_	_	_	_
14-22	2169-2179	displaying	_	_	_	_
14-23	2180-2183	the	substance[116]	new[116]	coref	17-2[0_116]
14-24	2184-2190	intra-	substance[116]	new[116]	_	_
14-25	2191-2194	and	substance[116]	new[116]	_	_
14-26	2195-2209	extra-cellular	substance[116]	new[116]	_	_
14-27	2210-2220	metabolite	substance[116]	new[116]	_	_
14-28	2221-2230	profiling	_	_	_	_
14-29	2231-2235	upon	_	_	_	_
14-30	2236-2239	IAV	substance|abstract[118]	giv|giv[118]	coref|coref|coref|coref	15-17|15-17[123_118]|15-17|15-17[123_118]
14-31	2240-2249	infection	abstract[118]	giv[118]	_	_
14-32	2250-2251	.	_	_	_	_

#Text=Little is known , however , about the systemic metabolic dynamics during the early stage of virus infection .
15-1	2252-2258	Little	_	_	_	_
15-2	2259-2261	is	_	_	_	_
15-3	2262-2267	known	_	_	_	_
15-4	2268-2269	,	_	_	_	_
15-5	2270-2277	however	_	_	_	_
15-6	2278-2279	,	_	_	_	_
15-7	2280-2285	about	_	_	_	_
15-8	2286-2289	the	abstract[120]	new[120]	_	_
15-9	2290-2298	systemic	abstract[120]	new[120]	_	_
15-10	2299-2308	metabolic	abstract|abstract[120]	giv|new[120]	_	_
15-11	2309-2317	dynamics	abstract[120]	new[120]	_	_
15-12	2318-2324	during	abstract[120]	new[120]	_	_
15-13	2325-2328	the	abstract[120]|abstract[121]	new[120]|new[121]	_	_
15-14	2329-2334	early	abstract[120]|abstract[121]	new[120]|new[121]	_	_
15-15	2335-2340	stage	abstract[120]|abstract[121]	new[120]|new[121]	_	_
15-16	2341-2343	of	abstract[120]|abstract[121]	new[120]|new[121]	_	_
15-17	2344-2349	virus	abstract[120]|abstract[121]|abstract|abstract[123]	new[120]|new[121]|giv|giv[123]	coref|coref|coref|coref	16-11|16-11[131_123]|16-11|16-11[131_123]
15-18	2350-2359	infection	abstract[120]|abstract[121]|abstract[123]	new[120]|new[121]|giv[123]	_	_
15-19	2360-2361	.	_	_	_	_

#Text=During our study , we analyze changes in metabolism upon influenza virus infection in human cells during the first infectious cycle via metabolomics .
16-1	2362-2368	During	_	_	_	_
16-2	2369-2372	our	person|abstract[125]	acc|new[125]	ana|ana	16-5|16-5
16-3	2373-2378	study	abstract[125]	new[125]	_	_
16-4	2379-2380	,	_	_	_	_
16-5	2381-2383	we	person	giv	ana	18-1
16-6	2384-2391	analyze	_	_	_	_
16-7	2392-2399	changes	abstract	new	_	_
16-8	2400-2402	in	_	_	_	_
16-9	2403-2413	metabolism	abstract[128]	giv[128]	coref	17-12[140_128]
16-10	2414-2418	upon	abstract[128]	giv[128]	_	_
16-11	2419-2428	influenza	abstract[128]|abstract|abstract[131]	giv[128]|giv|giv[131]	coref|coref|coref|coref	16-12|18-17[146_131]|16-12|18-17[146_131]
16-12	2429-2434	virus	abstract[128]|abstract|abstract[131]	giv[128]|giv|giv[131]	coref	18-43
16-13	2435-2444	infection	abstract[128]|abstract[131]	giv[128]|giv[131]	_	_
16-14	2445-2447	in	_	_	_	_
16-15	2448-2453	human	object[132]	giv[132]	_	_
16-16	2454-2459	cells	object[132]	giv[132]	_	_
16-17	2460-2466	during	_	_	_	_
16-18	2467-2470	the	abstract[133]	new[133]	_	_
16-19	2471-2476	first	abstract[133]	new[133]	_	_
16-20	2477-2487	infectious	abstract[133]	new[133]	_	_
16-21	2488-2493	cycle	abstract[133]	new[133]	_	_
16-22	2494-2497	via	abstract[133]	new[133]	_	_
16-23	2498-2510	metabolomics	abstract[133]|abstract	new[133]|new	_	_
16-24	2511-2512	.	_	_	_	_

#Text=Early metabolite analysis will throw new light on the activation of the innate immune metabolism .
17-1	2513-2518	Early	abstract[136]	new[136]	_	_
17-2	2519-2529	metabolite	substance|abstract[136]	giv|new[136]	_	_
17-3	2530-2538	analysis	abstract[136]	new[136]	_	_
17-4	2539-2543	will	_	_	_	_
17-5	2544-2549	throw	_	_	_	_
17-6	2550-2553	new	abstract[137]	new[137]	_	_
17-7	2554-2559	light	abstract[137]	new[137]	_	_
17-8	2560-2562	on	_	_	_	_
17-9	2563-2566	the	event[138]	new[138]	_	_
17-10	2567-2577	activation	event[138]	new[138]	_	_
17-11	2578-2580	of	event[138]	new[138]	_	_
17-12	2581-2584	the	event[138]|abstract[140]	new[138]|giv[140]	_	_
17-13	2585-2591	innate	event[138]|abstract[140]	new[138]|giv[140]	_	_
17-14	2592-2598	immune	event[138]|object|abstract[140]	new[138]|giv|giv[140]	_	_
17-15	2599-2609	metabolism	event[138]|abstract[140]	new[138]|giv[140]	_	_
17-16	2610-2611	.	_	_	_	_

#Text=We believe that the results of this work will elucidate the activation of innate immunity to viral infection from the perspective of the host and provide new control strategies for the development of novel drugs and the treatment and prevention of influenza virus infection .
18-1	2612-2614	We	person	giv	_	_
18-2	2615-2622	believe	_	_	_	_
18-3	2623-2627	that	_	_	_	_
18-4	2628-2631	the	abstract[142]	new[142]	_	_
18-5	2632-2639	results	abstract[142]	new[142]	_	_
18-6	2640-2642	of	abstract[142]	new[142]	_	_
18-7	2643-2647	this	abstract[142]|abstract[143]	new[142]|new[143]	_	_
18-8	2648-2652	work	abstract[142]|abstract[143]	new[142]|new[143]	_	_
18-9	2653-2657	will	_	_	_	_
18-10	2658-2667	elucidate	_	_	_	_
18-11	2668-2671	the	abstract[144]	new[144]	_	_
18-12	2672-2682	activation	abstract[144]	new[144]	_	_
18-13	2683-2685	of	abstract[144]	new[144]	_	_
18-14	2686-2692	innate	abstract[144]|abstract[145]	new[144]|giv[145]	_	_
18-15	2693-2701	immunity	abstract[144]|abstract[145]	new[144]|giv[145]	_	_
18-16	2702-2704	to	abstract[144]|abstract[145]	new[144]|giv[145]	_	_
18-17	2705-2710	viral	abstract[144]|abstract[145]|abstract[146]	new[144]|giv[145]|giv[146]	coref	18-42[156_146]
18-18	2711-2720	infection	abstract[144]|abstract[145]|abstract[146]	new[144]|giv[145]|giv[146]	_	_
18-19	2721-2725	from	abstract[144]|abstract[145]	new[144]|giv[145]	_	_
18-20	2726-2729	the	abstract[144]|abstract[145]|abstract[147]	new[144]|giv[145]|new[147]	_	_
18-21	2730-2741	perspective	abstract[144]|abstract[145]|abstract[147]	new[144]|giv[145]|new[147]	_	_
18-22	2742-2744	of	abstract[144]|abstract[145]|abstract[147]	new[144]|giv[145]|new[147]	_	_
18-23	2745-2748	the	abstract[144]|abstract[145]|abstract[147]|person[148]	new[144]|giv[145]|new[147]|giv[148]	_	_
18-24	2749-2753	host	abstract[144]|abstract[145]|abstract[147]|person[148]	new[144]|giv[145]|new[147]|giv[148]	_	_
18-25	2754-2757	and	_	_	_	_
18-26	2758-2765	provide	_	_	_	_
18-27	2766-2769	new	abstract[150]	giv[150]	_	_
18-28	2770-2777	control	person|abstract[150]	new|giv[150]	_	_
18-29	2778-2788	strategies	abstract[150]	giv[150]	_	_
18-30	2789-2792	for	abstract[150]	giv[150]	_	_
18-31	2793-2796	the	abstract[150]|abstract[151]	giv[150]|new[151]	_	_
18-32	2797-2808	development	abstract[150]|abstract[151]	giv[150]|new[151]	_	_
18-33	2809-2811	of	abstract[150]|abstract[151]	giv[150]|new[151]	_	_
18-34	2812-2817	novel	abstract[150]|abstract[151]|substance[152]	giv[150]|new[151]|new[152]	_	_
18-35	2818-2823	drugs	abstract[150]|abstract[151]|substance[152]	giv[150]|new[151]|new[152]	_	_
18-36	2824-2827	and	abstract[150]|abstract[151]	giv[150]|new[151]	_	_
18-37	2828-2831	the	abstract[150]|abstract[151]|abstract[153]	giv[150]|new[151]|new[153]	_	_
18-38	2832-2841	treatment	abstract[150]|abstract[151]|abstract[153]	giv[150]|new[151]|new[153]	_	_
18-39	2842-2845	and	abstract[150]|abstract[151]	giv[150]|new[151]	_	_
18-40	2846-2856	prevention	abstract[150]|abstract[151]|abstract[154]	giv[150]|new[151]|new[154]	_	_
18-41	2857-2859	of	abstract[150]|abstract[151]|abstract[154]	giv[150]|new[151]|new[154]	_	_
18-42	2860-2869	influenza	abstract[150]|abstract[151]|abstract[154]|abstract[156]	giv[150]|new[151]|new[154]|giv[156]	_	_
18-43	2870-2875	virus	abstract[150]|abstract[151]|abstract[154]|abstract|abstract[156]	giv[150]|new[151]|new[154]|giv|giv[156]	_	_
18-44	2876-2885	infection	abstract[150]|abstract[151]|abstract[154]|abstract[156]	giv[150]|new[151]|new[154]|giv[156]	_	_
18-45	2886-2887	.	_	_	_	_
